816468-24-3 Usage
Uses
Used in Pharmaceutical and Agrochemical Synthesis:
1-Boc-3-phenylamino-pyrrolidine is used as a building block for the creation of various pharmaceuticals and agrochemicals, leveraging its unique structural features to contribute to the development of new and effective compounds.
Used in Neurological Disorder Treatment:
1-Boc-3-phenylamino-pyrrolidine is studied for its potential use in the treatment of neurological disorders, indicating its possible role in medicinal chemistry for addressing conditions affecting the nervous system.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
In the field of asymmetric synthesis, 1-Boc-3-phenylamino-pyrrolidine is utilized as a chiral auxiliary, which is crucial for the selective synthesis of enantiomerically pure compounds, a key aspect in producing pharmaceuticals with desired biological activity and minimizing side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 816468-24-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,1,6,4,6 and 8 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 816468-24:
(8*8)+(7*1)+(6*6)+(5*4)+(4*6)+(3*8)+(2*2)+(1*4)=183
183 % 10 = 3
So 816468-24-3 is a valid CAS Registry Number.
816468-24-3Relevant academic research and scientific papers
Pyrrolidine integrin regulator and application thereof
-
Paragraph 0366-0370, (2021/09/08)
Disclosed are a compound as represented by formula I, and a racemate, a stereoisomer, a tautomer, an isotopic marker, a nitrogen oxide, a solvate, a polymorph, a metabolite, an ester, and a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same, a preparation method therefor, and the medical use thereof. The structure of formula I is as follows:
PDE9I WITH IMIDAZO PYRAZINONE BACKBONE
-
Page/Page column 40, (2013/04/25)
This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The pres
